M N Raber
Overview
Explore the profile of M N Raber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
1134
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Varadhachary G, Karanth S, Qiao W, Carlson H, Raber M, Hainsworth J, et al.
Int J Clin Oncol
. 2013 Jul;
19(3):479-84.
PMID: 23813044
Background: Carcinoma of unknown primary with a "gastrointestinal profile" is an emerging, favorable entity. Distinguishing this entity is of increasing significance given the progress in the treatment of colorectal cancer....
2.
3.
Hess K, Abbruzzese M, Lenzi R, Raber M, Abbruzzese J
Clin Cancer Res
. 1999 Dec;
5(11):3403-10.
PMID: 10589751
The clinical features and survival times of patients with unknown primary carcinoma (UPC) are heterogeneous. Therefore, the goals of this study were to apply a novel analytical method to UPC...
4.
Touroutoglou N, Gravel D, Raber M, Plunkett W, Abbruzzese J
Ann Oncol
. 1998 Nov;
9(9):1003-8.
PMID: 9818075
Background: The long intracellular half-life of gemcitabine's active metabolite, difluorodeoxycytidine triphosphate (dFdCTP), suggested that small increases in peak intracellular dFdCTP levels would have a profound effect on its intracellular area...
5.
Ayoub J, Hess K, Abbruzzese M, Lenzi R, Raber M, Abbruzzese J
J Clin Oncol
. 1998 Jun;
16(6):2105-12.
PMID: 9626210
Purpose: The objectives of this study were to identify prognostic factors for unknown primary tumor (UPT) patients with hepatic metastases, determine the common primary tumors identified, assess the yield of...
6.
Lenzi R, Kim E, Raber M, Abbruzzese J
Ann Oncol
. 1998 Apr;
9(2):213-6.
PMID: 9553668
Women with isolated metastatic carcinoma or adenocarcinoma involving axillary lymph nodes are a well-recognized group of unknown primary carcinoma (UPC) patients with a favorable prognosis. This group of patients are...
7.
Lenzi R, Hess K, Abbruzzese M, Raber M, Ordonez N, Abbruzzese J
J Clin Oncol
. 1997 May;
15(5):2056-66.
PMID: 9164218
Purpose: The objectives of this study were to assess clinical outcomes and prognostic factors in unselected, consecutive patients with poorly differentiated carcinoma (PDC) or poorly differentiated adenocarcinoma (PDA). Patients And...
8.
Abbruzzese J, Madden T, Sugarman S, Ellis A, Loughlin S, Hess K, et al.
Clin Cancer Res
. 1996 Sep;
2(9):1489-97.
PMID: 9816325
Topotecan, a semisynthetic water-soluble analogue of camptothecin, inhibits human topoisomerase I (topo I). We performed a Phase I clinical and plasma pharmacological study of topotecan administered by 24-h continuous infusion...
9.
Abbruzzese J, Abbruzzese M, Lenzi R, Raber M, Hess K
J Natl Cancer Inst
. 1996 Apr;
88(7):462-3.
PMID: 8618241
No abstract available.
10.
Perez-Soler R, Fossella F, Glisson B, Lee J, Murphy W, Shin D, et al.
J Clin Oncol
. 1996 Feb;
14(2):503-13.
PMID: 8636764
Purpose: This study was designed to assess the anti-tumor activity of topotecan (TPT) in patients with advanced non-small-cell lung cancer (NSCLC) previously untreated with chemotherapy. Patients And Methods: Patients with...